Form 8-K NEUROCRINE BIOSCIENCES For: Feb 11
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Neurocrine Bio. (NBIX) PT Lowered to $150 at Oppenheimer
February 14, 2022 8:30 AM ESTOppenheimer analyst Jay Olson lowered the price target on Neurocrine Bio. (NASDAQ: NBIX) to $150.00 (from $154.00) while maintaining an Outperform rating.
The analyst commented, "NBIX shares have outperformed in 2022 (+7% vs. NBI -14% and S&P 500 -7% YTD) based on a favorable setup that... More
Neurocrine Biosciences (NBIX) Misses Q4 EPS by 54c
February 11, 2022 7:32 AM ESTNeurocrine Biosciences (NASDAQ: NBIX) reported Q4 EPS of $0.04, $0.54 worse than the analyst estimate of $0.58. Revenue for the quarter came in at $303.5 million versus the consensus estimate of $320 million.
For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.
... More